chrisvoncsefalvay/vaers-outcomes huggingface dataset:
On 07/14/20, 18 yo F was seen in clinic for routine general medical examination. During this visit, pt was ordered Meningococcal B, recombinant OMV vaccine IM (BEXSERO). Per documentation, 0.5 mL was injected in left deltoid at 1343 (Lot #ABXA57AA; Exp: 9/30/2021). Pt tolerated injection without incident and was discharged home. On 07/15, pt's mother called the triage line and reported that pt developed "pain of a 10 immediately after the vaccination, has some patchy redness, and an area about 2-3 inches out from the injection site that is firm, tight, and warm to touch, raised a little. Although the pt denied any fever, SOB or other symptoms, pt acknowledged working out after injection. On 07/16, pt returned to clinic. Pt reported 10/10 arm pain described as a dull ache that worsens with movement. Pt self-medicated with ibuprofen 600 mg BID-TID without improvement. Pt exam found a small vaccine puncture mark visible in mid deltoid that was neither inflamed nor raised. Pt had decreased range of motion, tenderness (soft tissue tenderness over deltoid) and swelling (mild focal soft tissue swelling and erythema over deltoid). Pt had no sign of cellulitis, soft tissue infection or compartment syndrome. Pt had severe pain that is most c/w an injection site reaction that is causing rotator cuff involvement and shoulder impingement. Pt advised "diclofenac (VOLTAREN) 1 % topical gel; Apply 2 g topically 4 (four) times daily, Supportive care. Rest and avoid aggravating activities. Ibuprofen 3-4  tabs 3 x a day with meals for 1-4 week. Ice." Pt instructed to contact MD for any worsening pain, increasing redness, swelling, etc.
A widespread blistering rash to both arms and the upper torso, most closely spaced on the right deltoid region, with small clusters on his right side lumbar back, left low abdomen, and left deltoid, otherwise widely spread on the chest, abdomen and back.  These blisters have scabbed, and have the appearance of resolving Herpes Simplex or Zoster.  He has no illness sx.  The rash is itchy, more so when warm.
dementia; contracted the covid virus; contracted the covid virus; This is a spontaneous report from a Pfizer sponsored program. A contactable consumer (patient's wife) reported that a male patient of an unspecified age received BNT162B2 (Pfizer-BIONTECH Covid-19 Vaccine), with first dose in Dec2020 and with second dose on 19Jan2021, both via an unspecified route of administration at single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. It was reported that the patient received BNT162B2 3 weeks ago and got second dose on 19Jan2021, patient had dementia and contracted the COVID virus on 20Jan2021, patient had exposed to COVID 24-48 hours by a healthcare professional in the facility. The outcome of events was unknown.  Information on the Lot/Batch number has been requested.
Active chicken pox developed morning of 3/9/18. Patient presented with red fluid filled blisters, low grade fever and his right ear was slightly red.
Local swelling, itching and redness developed next day. Tx with antihistamine & sx resolved over next 2-3 days.
This case was reported by a consumer via call center representative and described the occurrence of headache in a 69-year-old male patient who received SHINGRIX. Previously administered products included ZOSTAVAX (patient had no reaction), pneumonia vaccine (patient had no reaction) and Tdap vaccine (patient had no reaction). Concurrent medical conditions included blood pressure and hyperlipidemia. Concomitant products included Atorvastatin and lisinopril. ON 19th February 2018, the patient received SHINGRIX. On 19th February 2018, less than a day after receiving SHINGRIX, the patient experienced pain in arm. On 20th February 2018, the patient experienced headache, muscle pain, fever, pain, chills, migraine and facial flushing. The patient was treated with ibuprofen. On 20th February 2018, the outcome of the headache was recovered/resolved. On an unknown date, the outcome of the muscle pain, fever, pain and chills were recovered/resolved and the outcome of the migraine was unknown and the outcome of the facial flushing and pain in arm were not recovered/not resolved. The reporter considered the headache, muscle pain, fever, pain, chills and migraine to be probably related to SHINGRIX. It was unknown if the reporter considered the facial flushing and pain in arm to be related to SHINGRIX. Additional information was reported as follows: The patient's arm hurt after vaccine administration. On 20th February 2018 morning, when the patient woke up, he had headache, muscle aches, pain and fever. One day after vaccination the patient experienced headache, muscle pain, fever, pain, chills, migraine and facial flushing. The body temperature was 99.8 degree F, the temperature was high for the patient as his temperature was usually below normal. The patient had chills and was covered in blanket. The patient took ibuprofen and had migraine earlier on the morning of reporting date. The patient's pharmacist. The batch number and the expiry date were not reported.
01/05/21: nausea 01/06/21: nausea and headache 01/07/21:nausea, head ache, muscle/joint pain
Patient received fluad that is for those 65 years old or older. she should not have received this vaccine.  No adverse effect to list
After 8-12 hours since injection a low grade fever 99-100 degrees began along with chills and aches in neck and back, body aches.
Injection for TDAP given 4/11/11. On 4/18/11 patient reports swelling, redness, itching at injection site. Advised ER by Dr., Dx reaction to Tdap, given BACTRIM, Prednisone and CLARITIN. D/C to home.
sore arm; This is a spontaneous report received from a contactable reporter(s) (Pharmacist) from medical information team.  A female patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: LIMB DISCOMFORT (non-serious), outcome "unknown", described as "sore arm". Additional Information:Patient got 2 booster doses of the Pfizer Biontech COVID19 vaccine within a week. It happened yesterday when patient about to get the flu shot. Response Stated that the information provided is not specific to 2 booster doses being administered but to inadvertent administration of higher than authorized dose. No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
weird skin; eczema; psoriasis; hives; This spontaneous case was reported by a consumer and describes the occurrence of ECZEMA (eczema), PSORIASIS (psoriasis), URTICARIA (hives) and SKIN DISORDER (weird skin) in a 43-year-old male patient who received mRNA-1273 (Spikevax) (batch no. ASKU) for COVID-19 prophylaxis.     The patient had no allergies or no disease. The patient received no other vaccines in the 4 weeks prior to COVID-19 vaccine.     On an unknown date, the patient received second dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 22-Sep-2022, the patient experienced ECZEMA (eczema), PSORIASIS (psoriasis) and URTICARIA (hives). On an unknown date, the patient experienced SKIN DISORDER (weird skin). At the time of the report, ECZEMA (eczema), PSORIASIS (psoriasis), URTICARIA (hives) and SKIN DISORDER (weird skin) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments.   The concomitant medication was not reported.  The treatment medication was not reported.
This spontaneous report was received from a licensed practical nurse and refers to a patient of unknown age and gender. The patient's concurrent conditions and medical history were not provided. It was reported that, on 12-MAY-2015, the patient was vaccinated with a first dose of GARDASIL Lot # reported as L013522, expiry date 13-SEP-2016 (dose, route and anatomical site of injection were not reported). The second dose of GARDASIL Lot # L001442, expiry date 04-NOV-2015, (dose, route and anatomical site of injection were not reported) was received on 16-JUN-2015. The third dose of GARDASIL Lot # K016966, expiry date 17-OCT-2017 (dose, route and anatomical site of injection were not reported), was received on 17-NOV-2015. Later, on 20-MAY-2016, the patient received a dose of GARDASIL 9 Lot # L048459, expiry date 01-JUN-2018 (lot number, dose, route and anatomical site of injection were not reported). Concomitant therapies were not provided. No adverse effects were reported. No product quality complain (PQC) was involved. Lot number L013522 is an invalid lot number for quadrivalent human papillomavirus (types 6, 11, 16, 18) recomb. vaccine.  Additional information has been requested.
THE VACCINE WAS INJECTED ON HER UPPER LEFT LEG. THE AREA WHERE SHE HAD THE VACCINE GOT INFECTED. IT WAS PURPLE AND RED AROUND IT. THE RED PART WAS ABOUT 1 INCH BIG. SHE ALSO GOT RED BUMPS ON HER BACK, FACE, STOMACH (LEFT RIB AREA), AND RIGHT UPPER LEG.THE RED BUMPS WERE YELLOW FROM THE MIDDLE AND A LITTLE BIT OF CLEAR LIQUID. ONE OF THE BUMPS ON HER BACK ALSO GOT INFECTED. THE DOCTOR GAVE HER SULFAMETHOXAZOLE-TMP TO TREAT INFECTION. SHE NEEDS TO TAKE THIS MEDICATION FOR 10 DAYS. TODAY IS HER 3ERD DAY TAKING IT AND HER INFECTION LOOKS A LOT BETTER. BESIDES THE RED BUMPS SHE WAS VERY IRRITABLE. BUT HAD NO FEVER OR LOSS OF APETITE.
Leg pain currently; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. Other Case identifier(s): US-PFIZER INC-202101466775.  A 53 year-old male patient received bnt162b2 (BNT162B2), intramuscular, administered in arm right, administration date 06Oct2021 16:00 (Lot number: FC3182) at the age of 53 years as dose 2, single for covid-19 immunisation. The patient had no relevant medical history. The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose 1, single, Date/Time: 15Sep2021/ 16:00 , Anatomical site of administration: Right shoulder, Route of administration: Intramuscular, Batch/Lot number: FD8448), administration date: 15Sep2021, when the patient was 53 years old, for COVID-19 immunisation, reaction(s): "Fatigue", "Joint pain", "Muscle pain", "Chest pain/tightness", "leg pain currently", "Some chest pain/tightness.".  The following information was reported: PAIN IN EXTREMITY (non-serious) with onset 2021, outcome "unknown", described as "Leg pain currently".  Additional information: Anatomical site of administration: Right shoulder  No follow-up attempts are possible. No further information is expected.
pt recvd vax & exp pain which spread to other joints & became severe; pt woke due to sharp pain; stabbing;
I got the vaccine at 8 AM that morning and I was fine until about 5PM and I got very cold. I was freezing. I had a chill.  I checked my temperature and it was around 99-100. During the night I woke up with a bad chill, I was really cold and I was shaking really bad. I checked my temperature and it was 102. Tuesday I checked my temperature all day it never went over 102. I took Ibuprofen all the day, no more then 4 tablets. I took a nap in the afternoon for about 2 hours and I when I woke up I was really cold and I was freezing and shaking. I was so cold my teeth were chattering. My mouth was very dry, I tried to drank a sip of water, which made me nauseous and I throw up slightly. My husband was concerned because he couldn't get me warm and he called our son. Our son came over, and asked do I know who he is and I responded no. I have reconciliation of my son coming over or my husband calling our son over to come check on me. My son immediately to called 911, EMS arrived  and they transported me to hospital. I do not remember any of this, I didn't become appear until I was stretcher , at that point I became aware and knew the answers to the questions being asked but I couldn't respond. I remember hearing the EMT say to turn the air on, I was burning up and had a temperature of 105. I was transported to  Medical Center. They run a lot of tests and they were trying to get my fever down. Sometime late that night they were finally able to my temperature down. I was released about 10 AM on Wednesday morning. I have been fine since then.  The doctors who all seen me in the ER all said they have not seen anything like this.
Very Sleepy right after shot.   I had trouble driving home.  Slept for 2 1/2 hours when I arrived home.
the patient was hospitalized / in serious condition with encephalitis; This spontaneous report was received from a physician and refers to a 14-year-old female patient. No information about the patient's pertinent medical history, concomitant medications and drug reactions or allergies was provided. The patient's immunization history was uncertain.  On an unknown date, the patient was vaccinated with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) (strength, dose, lot number and expiration date were not provided) intramuscularly for prophylaxis. The reporter was not sure if it was the patient's first dose or not but stated it was the only vaccine administered that day.  On an unspecified date, reported as a few days later or a few days after the vaccination, the patient was hospitalized in a serious condition for encephalitis. She was in the hospital for about 6 weeks, received an unspecified treatment and on an unknown date, was discharged. The patient fully recovered on an unknown date after leaving the hospital (reported as now back in school fully recovered).  The relatedness between the event of encephalitis and the suspect vaccine was not provided.  Upon internal review, the event of encephalitis was considered to be medically significant.
Pfizer 3/20 and 4/17. Positive on 1/1/22
Post vax the patient developed a swollen arm, painful to touch. The patient was treated with Tylenol and recovered.
1005: Complaint of dizziness; BP 160/90s, P 115. No SOB or respiratory difficulty. No rash. Patient anxious.  1030: Red, raised rash noted to begin on forehead, cheeks, and upper chest. Shaking (slightly) noted in hands. Patient states "feeling cold." BP 162/94, P 108, O2 99% RA. Patient A&Ox3 sitting in chair.  1040: Patient complaint of "lips feeling 'tingly'". Quickly progressed to full facial tingling. Denies dyspnea or chest pain. Still states she " feels dizzy." 911 called. BP 142/88, P 95, O2 99% RA.  1045: Turned over to paramedics. Patient A&Ox3. Rash still present but no worse. Denies dyspnea or chest pain. Still shaky, slight diaphoresis. Husband & son with patient. Patients belongings given to husband. Taken by EMS offsite.
Information has been received from a physician concerning a 5 year old male who was vaccinated with a second dose of VARIVAX (Merck). The patient fainted after receiving the VARIVAX (Merck). The patient sought medical attention through an office visit. At the time of this report the patient had recovered. Additional information has been requested.
Red "bump" over site of injection right leg. 1 week later - formation of 2 "x 1.5" irregular plaque-like skin reaction-irregular border. Area is raised, welt-like with darker red border. Causes itching, but no fever, child is active.
45 yo f c/o increased redness/pain to covid19 vaccination site on L upper arm/shoulder (deltoid region) from vaccine given at center approx 72hrs pta, states uncomplicated administration of dose (1st in shot series) but had increasing fevers/chills and general malaise over next 24-36hrs, then felt improving, but returned 24hrs pta; came to ED yesterday but did not want to check in, had nursing staff mark arm w/skin marker, and redness has spread outside the borders; Pt reports taking motrin/tylenol w/o sig improvement in sx's; Pt denies any distal numbness/tingling/weakness, prior hx of vaccine adverse events
left axillary rash; heat rash; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of rash in a 66-year-old male patient who received RSVPreF3 adjuvanted (Arexvy) (batch number 5BN3T, expiry date 05-NOV-2024) for prophylaxis.   On 19-SEP-2023, the patient received Arexvy (intramuscular, left deltoid). On 21-SEP-2023, 2 days after receiving Arexvy, the patient experienced rash (Verbatim: left axillary rash) and heat rash (Verbatim: heat rash).  The patient was treated with hydrocortisone cream and topical antibiotic (nos) (Antibacterial Soap). The outcome of the rash and heat rash were not resolved.   It was unknown if the reporter considered the rash and heat rash to be related to Arexvy.     It was unknown if the company considered the rash and heat rash to be related to Arexvy.   Additional Information: GSK Receipt Date: 29-SEP-2023 The reporter reported that the patient received Arexvy vaccine and he developed left axillary rash, which remains ongoing at the time of reporting. The patient reported that it looks like a heat rash. Patient had used hydrocortisone cream and washed with antibacterial soap, but the rash remains unchanged. The vaccine administration facility was the same as primary reporter. The reporter consented to follow up.
Arm pain; headache; tiredness; extreme weakness; This is a spontaneous report from a contactable consumer (reported for herself). A 73-year-old female patient (not pregnant at the time of vaccination) received the first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EH9899), via an unspecified route of administration on 05Jan2021 13:15 at single dose at left arm for COVID-19 immunization. Medical history included High cholesterol, Fibromyalgia, Protein S Deficiency, Anxiety, known allergies: Scallops. Concomitant medications received in two weeks included warfarin, esomeprazole magnesium (NEXIUM [ESOMEPRAZOLE MAGNESIUM]), fluoxetine, clonazepam (KLONOPIN), rosuvastatin calcium (CRESTOR), fenofibrate (FENOFIBRAT). Facility where the most recent COVID-19 vaccine was administered: Other. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 06Jan2021, the patient experienced Arm pain, headache, tiredness, extreme weakness. No treatment was received for the adverse events. The report was non-serious per the reporter. Prior to vaccination, the patient wasn't diagnosed with COVID-19. Since the vaccination, the patient hadn't been tested for COVID-19. The outcome of the events was not recovered.
w/in 48hr of vax pt devel urticaria on rt arm;the vaccine inj site on lt arm was warm;
numbness developed right lip  and advanced to sagging right side  and right eye would not close late day after injection, (Note I also received the flu vaccination in my left arm same day.)  Symptoms worsened over weekend. Went to ER on Monday. Saw Dr. very brief'  , no other testing "confidently" diagnosed it as bell's Palsy. Prescribed steroids and eye drops once every hour.  I am seeing my primary care Dr. on Friday at her recommendation for more detailed medical advice.
Headache, fever/chills 100.9, lethargy/malaise, dizziness/nausea - took approximately 24 hours to recover.
SIDE EFFECTS; VACCINE EXPOSURE VIA BREAST MILK; SLEEPY; MORE TIRED; This spontaneous report received from a consumer via other company (Moderna) concerned a female of an unspecified age, race and ethnicity. The patient's height, and weight were not reported. The patient's pre-existing medical conditions included: The patient was non pregnant at the time of vaccine exposure. The patient's parent received covid-19 vaccine ad26.cov2.s (dose number in series 1) (dose 1) (suspension for injection, transmammary (patient's route of admin), batch number: unknown and expiry: UNKNOWN) first dose, 1 total, dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported. Consumer stated patient was a nursing toddler.  On an unspecified date, the patient experienced vaccine exposure via breast milk (dose number in series 1). Consumer mentioned after received all COVID-19 vaccinations, toddler experienced side effects since she was nursing at the time of vaccination (dose number in series 1). The patient's parent received first booster dose of non-company suspect Moderna covid-19 vaccine (Elasomeran) (dose number in series 2) (dose 2) (form of admin, transmammary (patient's route of admin), batch number: unknown and expiry: UNKNOWN) dose was not reported, administered on 16-DEC-2021 for prophylactic vaccination. On 17-Dec-2021, the patient became more tired than normal and sleep more (24 hours after received the Moderna booster dose) (dose number in series 2).  The patient's parent received second booster dose non-company suspect Pfizer biontech covid-19 vaccine (tozinameran) (dose number in series 3) (dose 3) (form of admin, transmammary (patient's route of admin), batch number: unknown and expiry: UNKNOWN) dose was not reported, administered on 27-MAY-2022 for prophylactic vaccination. On an unspecified date in 2022, the patient experienced side effects after the Pfizer dose also (dose number in series 3). It was reported that the patient (child), had not received any COVID-19 vaccinations at the time of this report. The action taken with covid-19 vaccine ad26.cov2.s, Elasomeran, and Tozinameran was not applicable. The outcome of the side effects, vaccine exposure via breast milk, more tired and sleepy was not reported. This report was non-serious.    .
I have Sjogren's syndrome and eat a low-sodium diet because it helps with the dryness. A few weeks after the vaccine I had a slowly encroaching hyponatremia and hypokalemia set in, without realizing it until it was too late and I wound up in the ER. My thirst was slowly growing and I drank more and more water. I only realized that the abnormal thirst may be from low sodium until it was too late. I could be incorrect, but I highly suspect that maybe the PEG in the vaccine dropped my sodium and I did not replenish it from my diet, but only worsened it with water drinking.
Information has been received from a published article. BACKGROUND: Transmission of vaccine-strain varicella-zoster-virus (VZV) had rarely been documented, with only 10 published laboratory-confirmed cases, all of which occurred among close contacts of vaccine recipients who developed post-vaccination rash. The authors described a unique case of vaccine-strain varicella resulting from exposure to a vaccinated individual who reported no rash post vaccination. RESULTS: A 25-day-old healthy female infant developed varicella 22 days after her mother was vaccinated in the immediate postpartum period. The infant developed a vesicular rash with 50-60 lesions. She was afebrile, had no complications was not hospitalized, and recovered completely. Infection with vaccine-strain VZV was confirmed by strain-specific PCR of cutaneous lesions. Her mother had no post-vaccination symptoms, rash or itching. The infant had no known contact with other persons with rash (varicella or zoster) or recent varicella vaccination other than her mother. CONCLUSIONS: This was the first reported case of secondary transmission of vaccine-strain VZV from a vaccine recipient who developed no rash illness. Possible mechanisms for transmission included aerosolization of the vaccine during administration, transference of vaccine fluid from the mother's arm to the infant's mucosa immediately after vaccination, passage through break milk or transmission through maternal respiratory secretions. The possibility of rare transmission of vaccine-strain VZV to a neonate should not discourage post-partum vaccination programs as the risk of complications from wild-type VZV illness greatly exceeds the risk of neonatal infection by vaccine-strain VZV. Additional information has been requested.
pt recvd vax & esp stiff neck & muscle aches 7 days p/vax;no further details were provided;
VAERS completed because of being Tested positive for COVID-19 infection 14 or more days after being fully vaccinated. 1st dose12/23/21 2nd dose01/13/21 Diagnosed covid positive:09/13/21 Symptom onset:09/10/21 Exposure: Symptoms:cough, fatigue,loss of smell/taste,sore throat, HA